One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Game changer epidemiological studies
Filippo Crea
doi : 10.1093/eurheartj/ehad739
European Heart Journal, Volume 44, Issue 42, 7 November 2023, Pages 4393–4397
An Indian female cardiologist’s journey from ‘TAWA’ to ‘TAVI-transcatheter aortic valve implantation’
Shibba Takkar Chhabra 1*, Aastha Takkar2, and Rajesh Chand Arya
The European Society of Cardiology working group on cardiovascular pharmacotherapy
Juan Carlos Kaski 1*, Alexander Niessner 2, Dobromir Dobrev 3,4,5, and Bianca Rocca
Artificial intelligence and deep learning: Wittgenstein beats Plato
Thomas F. Lüscher 1,2,3,4* and Florian A. Wenzl
Physical activity patterns and cardiovascular health: ‘yes, weekend!’
Rocco Vergallo 1,2* and Leonarda Galiuto
Significance of lipids, lipoproteins, and apolipoproteins during the first 14–16 months of life
Sofie Taageby Nielsen 1, Rikke Mohr Lytsen1, Nina Strandkj?r2, Ida Juul Rasmussen 1,3, Anne-Sophie Sillesen 2, R. Ottilia B. V?gg 2, Anna Axelsson Raja 4, B?rge G. Nordestgaard 3,5, Pia R. Kamstrup 3, Kasper Iversen 2,5, Henning Bundgaard 4,5, Anne Tybj?rg-Hansen1,5, and Ruth Frikke-Schmidt
Plasma cholesterol levels in infancy: a neglected resource
Kirsten B. Holven
Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation
Jianhua Wu 1*, Ramesh Nadarajah 2,3,4, Yoko M. Nakao2,3, Kazuhiro Nakao2,3, Chris Wilkinson5,6, J. Campbell Cowan4, A. John Camm7, and Chris P. Gale
Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges
Pascal B. Meyre1,2 and David Conen
Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries
Darryl P. Leong 1,2*, Philip Joseph1,2, John J.V. McMurray3, Jean Rouleau4, Aldo P. Maggioni5, Fernando Lanas 6, Sanjib K. Sharma 7, Julio N??ez 8, Bishav Mohan9, Ahmet Celik10, Jabir Abdullakutty11, Okechukwu S. Ogah12, Lisa M. Mielniczuk13, Kumar Balasubramanian1, Tara McCready1, Alex Grinvalds1, and Salim Yusuf1,2; on behalf of the G-CHF Investigators
Frailty: a new vital sign in heart failure comes of age
Finlay A. McAlister
Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality
Shishir Rao 1,2*, Milad Nazarzadeh 1,2, Dexter Canoy3, Yikuan Li1,2, Jing Huang1,4, Mohammad Mamouei1,2, Gholamreza Salimi-Khorshidi1,2, Aletta E. Schutte5, Bruce Neal5, George Davey Smith6,7, and Kazem Rahimi
Deep learning approach to unmask hidden salt effects in the era of artificial intelligence
Athanasios J. Manolis* and Manolis S. Kallistratos
Smoking and cardiovascular outcomes after percutaneous coronary intervention: a Korean study
You-Jeong Ki 1†, Kyungdo Han 2†, Hyo-Soo Kim 3,4, and Jung-Kyu Han
Where there is smoke there is risk: is there an irreversible threshold?
Xavier Garcia-Moll
Lack of association between fluoroquinolone and aortic aneurysm or dissection
Kyungmin Huh 1, Minsun Kang 2, and Jaehun Jung
Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated
Juan Tamargo1 and Stefan Agewall 2
Limited-resource, limited-guideline? Towards the delivery of appropriate and contextual cardiovascular care across settings
Dominique Vervoort
Coronary manifestations of immunoglobulin G4-related disease
Daigo Hiraya *, Hiroaki Watabe , and Tomoya Hoshi
Constrictive pericarditis: mitral inflow and septal shudder as diagnostic red flags and evolution of echocardiographic and clinical data after treatment
Iwona Duraj1, Daniel Steter2, and Karina Wierzbowska-Drabik
Correction to: 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)
